Previous Article | Next Article 
Infection and Immunity, July 2008, p. 3268-3272, Vol. 76, No. 7
0019-9567/08/$08.00+0 doi:10.1128/IAI.00244-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Presence of Wild-Type and Attenuated Salmonella enterica Strains in Brain Tissues following Inoculation of Mice by Different Routes
Wendy S. Bollen,1,
Bronwyn M. Gunn,1,2,
Hua Mo,2
Margarita K. Lay,1,
and
Roy Curtiss III1,2*
Department of Biology, Washington University, St. Louis, Missouri 63130-4899,1
School of Life Sciences and Biodesign Institute, Arizona State University, Tempe, Arizona 85287-54012
Received 20 February 2008/
Returned for modification 16 April 2008/
Accepted 5 May 2008

ABSTRACT
Salmonella enterica serovar Typhi and Typhimurium vaccine candidates
elicit significant immune responses in mice by intranasal (i.n.)
immunization. Because of the proximity of the cribriform plate
of the ethmoid bone, we were concerned that
Salmonella bacteria
delivered i.n. might access the brain. Accordingly, wild-type
and attenuated (by single and double mutations) strains of
S. enterica serovars Typhimurium and Typhi were recovered at low
numbers initially from the olfactory lobe and then from the
brain for 3 to 4 days after i.n. immunization. This was independent
of
invA gene function. Although the presence of bacteria in
blood 1 to 3 h after i.n. inoculation was sometimes observed,
this was infrequent compared to the frequency of bacteria detected
in brain tissues. In confirmation of recent observations by
Wickham et al. (M. E. Wickham, N. F. Brown, J. Provias, B. B.
Finlay, and B. K. Coombes, BMC Infect. Dis.
7:65, 2007) that
oral inoculation with wild-type
S. enterica serovar Typhimurium
strains lead to bacteria in blood with subsequent colonization
of brain tissues with neurological symptoms of disease, we found
similar results by using the i.n. and intraperitoneal (i.p.)
routes of inoculation for wild-type but not for attenuated strains
of
S. enterica serovar Typhimurium. In contrast, a highly modified
attenuated
S. enterica serovar Typhimurium strain was not present
in brain tissues when administered at higher doses by the oral,
i.n., and i.p. routes than the wild-type strain even though
the presence of bacteria in blood was detectable 1 to 3 h after
inoculation by each of the three routes. Our results indicate
that i.n. and possibly even oral delivery of live
Salmonella vaccines may be unsafe although it is possible to reduce this
risk by appropriate genetic modifications.

INTRODUCTION
Attenuated strains of
Salmonella have been widely investigated
for use as oral vaccines and as live vectors to deliver antigens
because of their ability to induce mucosal, humoral, and cell-mediated
immune responses (
4,
5,
19,
20). Preclinical studies have shown
that intranasal (i.n.) immunization of mice with attenuated
recombinant
Salmonella enterica serovar Typhi and Typhimurium
vaccine vectors induced excellent immune responses to the expressed
antigens, as well as to
Salmonella antigens (
10,
15,
22,
23,
26). Since the cribriform plate is a fragile, well-hidden bone
in the nasal cavity with numerous perforations that allow passage
of the olfactory nerves to the brain, there exists a potential
route for
Salmonella bacteria to enter the cranial cavity if
administered i.n. We therefore evaluated strains of
S. enterica serovars Typhimurium and Typhi attenuated by several different
means, as well as their wild-type parents, for the ability to
reach the brains of BALB/c and Swiss Webster mice after i.n.
inoculation and investigated the route of brain access by colonization
of the olfactory bulbs versus access through the circulatory
system (
25,
29).
As reported in the clinical literature, meningitis is occasionally a consequence of presumably oral S. enterica serovar Typhi infection, especially in young children (7, 13, 18, 21). Recently, Wickham et al. (30) reported that oral infection of mice with wild-type S. enterica serovar Typhimurium strains can cause meningoencephalitis. We have confirmed these observations and determined that such infections also arise after inoculation with wild-type strains by the i.n. and i.p routes. Another question of interest is whether substantially modified vaccine strains might still be able to cause infections that result in brain colonization or neurological disease symptoms. We have addressed these issues and report our findings here.
(The findings reported here were briefly communicated earlier [2].)

MATERIALS AND METHODS
Bacterial strains and media.
The
S. enterica serovar Typhimurium UK-1 and
S. enterica serovar
Typhi strains used in this study and their respective genotypes
are listed in Table
1. The mutants or wild-type strains were
grown with aeration to late log phase in LB broth (
1) at 37°C.
Buffered saline with gelatin (BSG) (
3) was used as a diluent
and to suspend bacteria prior to inoculation of mice.
Mice and inoculation methods.
Six- to 7-week-old female BALB/c and Swiss Webster mice (Charles
River Laboratories, Wilmington, MA) were maintained in Nalgene
filter-covered isolators for 1 week prior to infection. The
rodent suite was maintained at 22 to 23°C with 12 h of illumination
daily. Bacterial strains were grown as overnight standing cultures
that were diluted 1 to 100 in prewarmed LB broth and grown with
mild aeration to an optical density at 600 nm of 0.8 to 0.9.
Bacteria were sedimented by centrifugation at room temperature
and resuspended in BSG to densities appropriate for the inoculation
route and dose. Mice were fasted for food and water for 4 h
prior to inoculation. Ten microliters of

10
9 CFU of
S. enterica serovar Typhimurium or Typhi suspended in BSG was administered
i.n. (5 µl per nare) to mice without anesthesia. This
method ensures nasal delivery and avoids delivery of bacteria
to the lungs, as occurs when using larger volumes and/or anesthesia.
In some experiments, lower doses of CFU were administered. Doses
of 10
5 to 10
9 CFU in 20 µl were used for oral inoculation,
and doses of 10
3 to 10
6 CFU in 50 µl were used for intraperitoneal
(i.p.) inoculation with lower doses of wild-type virulent strains
than of attenuated strains. Food and water were returned 30
min after inoculation. Mice were euthanized via asphyxiation
with CO
2 and necropsied at various times.
Analysis of brain tissues for the presence of bacteria.
All incisions in euthanized mice were made with flame-sterilized scissors on the dorsal side of the mouse directly into the brain cavity. Brain tissues were extracted by slipping flame-sterilized forceps under the brain and gently pulling the brain toward the neck and then out of the brain cavity. The nose and respiratory pathway were left intact and undisturbed. Brain tissues were washed in 1 ml of sterile BSG in 24-well plates. The cerebrum and cerebellum were resuspended in sterile BSG until homogenization. In some studies, the olfactory lobe was separated from the remainder of the brain for separate analysis. The homogenizer (Brinkmann, Westbury, NY) was washed with 5% Amphyl, followed by a wash with 70% ethanol, followed by two washes with distilled H2O. Homogenized tissues were plated onto MacConkey agar-1% lactose plates. Salmonella colonies were white on the MacConkey agar plates. Isolated colonies were further identified by agglutination with Salmonella O antiserum.
Analysis of blood for the presence of bacteria.
Fifty-microliter samples of blood were taken from the saphenous veins of anesthetized mice. These samples were directly plated on MacConkey agar-1% lactose.

RESULTS
Presence of bacteria in brain tissues following i.n. inoculation.
Figure
1 shows data on the recovery of the
S. enterica serovar
Typhimurium UK-1 and SL1344 wild-type (

3761 and

3339) and mutant
strains from the brains of mice after i.n. infection. High numbers
of

4402
invA::Km mutant cells were recovered from the brains
on days 4 and 4.5, indicating that the
inv locus (
9) does not
play a role in the ability of
Salmonella bacteria to colonize
the brain. However, the highly attenuated
phoP233 mutant strain

8768 colonized the brains of mice at lower numbers on days 1
and 3.5 compared to the wild-type and
invA mutant strains (Fig.
1). Lastly, the avirulent and highly immunogenic UK-1
cya-
27
crp-
27 mutant strain

8132, in the few animals inoculated, was
not observed to colonize the brains of BALB/c mice after i.n.
inoculation at days 1, 2, and 3 (Fig.
1).
Figure
2 presents data on the recovery of
S. enterica serovar
Typhi mutants from the brains of mice after i.n. inoculation
with 10
9 CFU of ISP1820, Ty2 (which is RpoS
–), and a Ty2
RpoS
+ derivative. Isolated colonies were further identified
by agglutination with
Salmonella Vi antiserum. The Ty2 wild-type
strain was recovered in higher numbers at 1 and 3 h after i.n.
inoculation than was its RpoS
+ derivative

8438. Therefore, it
is evident that the sigma factor RpoS, which regulates virulence
in
S. enterica serovar Typhimurium (
8) and also mediates the
stationary-phase expression of many genes, including resistance
to low pH, oxidation, and starvation (
14), has no appreciable
effect on the access of
Salmonella bacteria to the brain. After
i.n. inoculation with 10
9 CFU, the

8542
phoP24 mutant
S. enterica serovar Typhi strain was isolated in higher numbers from the
brains of mice at 45 min and 1 h than were any of the wild-type
strains, indicating that the highly attenuating
phoP24 mutation
has no apparent ability to diminish the access of
S. enterica serovar Typhi to the brain. This observation was in contrast
to the reduced brain-colonizing ability of
phoP233 mutant
S. enterica serovar Typhimurium

8768 (Fig.
1). ISP1820 and the
ISP1820 derivative

8110, with
cya and

(
crp-
pabA) attenuating
mutations, colonized the brains of mice to a lesser extent than
did the
phoP mutant strains but was not evaluated a sufficient
number of times to allow any conclusions concerning its relative
brain-accessing ability. Overall, 102 of 170 mice inoculated
i.n. were positive for the presence of
Salmonella bacteria in
the brain.
Initial colonization of the olfactory bulb.
In a separate series of experiments, we separated the olfactory
bulb from the remainder of the brain prior to the homogenization
and enumeration of bacteria. In an analysis of 96 mice inoculated
with doses ranging from 10
7 to 10
9 CFU, 27 had detectable
Salmonella bacteria in olfactory lobe tissue and only 18 had
Salmonella bacteria in the remainder of the brain tissue (Table
2). In
no case did we detect
Salmonella bacteria in brain tissue in
the absence of detection of
Salmonella bacteria in the olfactory
lobe of the same mouse. This study provides support for the
belief that
Salmonella bacteria access the brain following i.n.
inoculation by traversing the olfactory nerve through the cribriform
plate to the olfactory bulb.
Potential for blood being the conduit for Salmonella bacteria accessing the brain.
In several i.n. infections with 10
9 CFU, we failed to detect
any
Salmonella bacteria in 100-µl samples of blood analyzed
1 and 3 days after inoculation. However, since oral inoculation
of mice with wild-type
S. enterica serovar Typhimurium can lead
to bacteria in blood (
29) very soon after infection and blood-borne
S. enterica serovar Typhimurium can infect brain tissue (
25),
we investigated whether i.n. inoculation could lead to the presence
of bacteria in blood soon after inoculation. As shown by the
data in Table
3, both wild-type
S. enterica serovar Typhimurium
and a highly attenuated strain can be detected in blood 1 and
3 h after infection by the oral, i.n., and i.p. routes. In addition,
all three routes of infection lead to the presence of bacteria
in brain tissues 24 and 72 h after infection by the wild-type
strain but not after infection by the highly attenuated mutant

9558(pYA4088). In these studies, we did not investigate the
behavior of attenuated strains having a single attenuating mutation,
as was done for the studies reported in Fig.
1, but presume
we might have found bacteria in blood and bacteria in olfactory
bulb and brain tissues. However, in numerous studies, we have
never observed neurological symptoms as described below when
inoculating 10
9 CFU of a diversity of attenuated
S. enterica serovar Typhimurium strains via the oral route of inoculation.
It should be reiterated that we were scrupulous in avoiding
blood contamination of brain tissues during their removal and
also washed tissues with buffer prior to their homogenization.
Nevertheless, it appears that wild-type and attenuated
Salmonella strains can access brain tissue by trafficking up the olfactory
nerve through the cribriform plate to the olfactory bulb and
then to the brain or, in the case of wild-type strains, at least,
by traversing through blood to penetrate the blood-brain barrier
to access brain tissues.
View this table:
[in this window]
[in a new window]
|
TABLE 3. S. enterica serovar Typhimurium entry into the blood and brains of BALB/c mice depending on the route of inoculationa
|
Neurological disease symptoms in mice caused by S. enterica serovar Typhimurium infection.
Mice infected by the oral, i.n., and i.p. routes with doses
of the wild-type
S. enterica serovar Typhimurium strain

3761
that were near the 50% lethal dose for those routes of infection
occasionally developed signs of neurological disease. For example,
4 of 25 BALB/c mice that ultimately died or were euthanized
after the administration of oral doses of 1.2
x 10
4, 1.2
x 10
5,
and 1.2
x 10
6 CFU of

3761 (10 mice per dose) showed neurological
signs of illness (twirling, rolling, jumping, loss of motor
control, etc.) and had high numbers of bacteria in brain tissues,
as well as in the Peyer's patches, mesenteric lymph nodes, spleen,
and liver. In this study, four of nine mice euthanized 10 days
after inoculation also had bacteria cultured from brain tissues
but at a lower mean titer (4
x 10
3 CFU) than the mice euthanized
with neurological symptoms (1.3
x 10
4 CFU). These results confirm
and extend the observations of Wickham et al. (
30) that wild-type
strains of
S. enterica serovar Typhimurium can cause meningoencephalitis
when infection is by diverse routes, including the i.n. route.
Neurological symptoms have so far been undetected in mice inoculated by any route at doses up to those used for the studies in Table 3 with the attenuated vaccine strain
9558(pYA4088). This strain, although able to access blood, also has so far been undetected in brain tissues independent of the route of inoculation.

DISCUSSION
In evaluating the ability of
S. enterica serovars Typhimurium
and Typhi to access the brain after i.n. inoculation, the number
of bacteria present in the brains of individual mice was highly
variable. The number of
S. enterica serovar Typhi CFU per gram
of brain tissue was lower than that of
S. enterica serovar Typhimurium,
and
S. enterica serovar Typhimurium was isolated from the brain
at later time points than
S. enterica serovar Typhi. These observations
can be attributed to the host specificity of
S. enterica serovar
Typhi such that mice are able to survive high doses of
S. enterica serovar Typhi administered by various routes whereas this bacterium
causes a systemic infection and typhoid fever in humans. In
contrast,
S. enterica serovar Typhimurium causes gastroenteritis
in humans but causes a systemic infection similar to human typhoid
fever in mice. Lastly, despite the means of attenuation by single
or double mutations,
S. enterica serovar Typhimurium and
S. enterica serovar Typhi were able to access the brains of BALB/c
mice and persist for a number of days. Based on our results,
it is evident that i.n. inoculation of
Salmonella bacteria into
BALB/c and Swiss Webster mice permits the entry of both wild-type
virulent and attenuated (by single and double mutations)
Salmonella strains into the brain. This has previously been shown for intravenous
(
25) and oral (
30) infections with wild-type virulent
S. enterica serovar Typhimurium strains, and we have extended this to i.p.
infection in this study. Although the number of
Salmonella CFU
per gram of brain tissue in our studies was variable and low,
all of the
S. enterica serovar Typhimurium and Typhi mutant
and wild-type strains used, with the exception of strains

8132
and

9558, were capable of colonizing the brains of BALB/c mice.
Moreover, all of the serotypes of
Salmonella have been associated
with occasionally causing bacterial meningitis and have been
isolated from the cerebrospinal fluid of humans (
7,
21). Meningitis
is an unusual complication of typhoid fever, with the majority
of cases involving newborns and young infants and being associated
with significant mortality (
7,
13,
18). However, 5 to 35% of
adult typhoid fever patients have signs and symptoms associated
with the central nervous system such as seizure or acute psychotic
behavior, confusion, and dizziness, usually occurring within
the first few days of fever (
28). In addition, a significant
percentage of the patients who survive
Salmonella meningitis
suffer permanent neurological deficits (
17). The results reported
by Wickham et al. (
30) and those in this report reveal that
multiple routes of infection with wild-type
S. enterica serovar
Typhimurium can all lead to meningitis in mice. By the intravenous,
i.p., and oral inoculation routes, it appears that bacteria
enter the circulatory system and somehow pass the blood-brain
barrier to colonize brain tissues. In several i.n. infections
with 10
9 CFU of both wild-type and attenuated
S. enterica serovar
Typhimurium strains, we failed to detect any
Salmonella bacteria
in 100-µl samples of blood analyzed 1 and 3 days after
inoculation. However, as shown by the data in Table
3, we did
detect both wild-type and attenuated strains in blood 1 and
3 h after i.n. inoculation. Thus, although we observed the sequential
presence of
Salmonella bacteria on olfactory bulbs before their
presence in higher brain tissues (Table
2), it remains possible
that brain colonization following i.n. inoculation could be
by either hematogenous or nonhematogenous routes.
Since the i.n. route of inoculation is an attractive route for vaccination due to the induction of excellent mucosal and systemic immune responses, it should continue to be used to evaluate the immunogenicity of antigens presented by host-adapted live attenuated bacterial vaccine candidates in various animal species such as mice. However, further evaluation of the safety of i.n. inoculation in human clinical trials remains to be discussed and further research is needed to evaluate new means of attenuating live bacterial vaccines to preclude colonization of the brain. Also of importance is a more careful analysis of orally administered attenuated vaccine strains to demonstrate that they fail to access brain tissues even though neurological symptoms are absent. In this regard, we have so far not observed such colonization of brain tissues or induction of neurological symptoms with an extensively modified attenuated S. enterica serovar Typhimurium strain being developed as safe for more disease-susceptible ages, physiological states, and genotypes of mice (12). This strain,
9558(pYA4088), is very immunogenic, and its safety properties and excellent attributes as an antigen delivery vector will be the subject of other publications from our group.

ACKNOWLEDGMENTS
We thank Shelley Haydel and Josephine Clark-Curtiss for critical
review of the manuscript and Daniel Piatchek and Jack Diani
at WU and Jacki Kilbourne at ASU for assistance with the animal
experiments.
This research project was supported by grants from the National Institutes of Health (R01 DE06669 and R01 AI024533) and the Bill and Melinda Gates Foundation (37863).

FOOTNOTES
* Corresponding author. Mailing address: The Biodesign Institute, Center for Infectious Diseases and Vaccinology, Arizona State University, P.O. Box 875401, 1001 S. McAllister Avenue, Tempe, AZ 85287-5401. Phone: (480) 727-0445. Fax: (480) 727-0466. E-mail:
rcurtiss{at}asu.edu 
Published ahead of print on 12 May 2008. 
Editor: F. C. Fang
Present address: Agnesian Healthcare, Fond du Lac, WI 54935. 
Present address: Department of Microbiology and Immunology, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599. 
Present address: Departments of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030-3498. 

REFERENCES
1 - Bertani, G. 1951. Studies on lysogenesis. I. The mode of phage liberation by lysogenic Escherichia coli. J. Bacteriol. 62:293-300.[Free Full Text]
2 - Bollen, W. S., B. Gunn, M. Lay, and R. Curtiss III. 2003. Colonization of the brain following intranasal inoculation with Salmonella, abstr. E-088, p. 265-266. Abstr. 103rd Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.
3 - Curtiss, R., III. 1965. Chromosomal aberrations associated with mutations to bacteriophage resistance in Escherichia coli. J. Bacteriol. 89:28-40.[Abstract/Free Full Text]
4 - Curtiss, R., III. 1990. Attenuated Salmonella strains as live vectors for the expression of foreign antigens, p. 715-740. In G. C. Woodrow and M. M. Levine (ed.), New generation vaccines. Marcel Dekker, New York, NY.
5 - Curtiss, R., III., T. Doggett, A. Nayak, and J. Srinivasan. 1996. Strategies for the use of live recombinant avirulent bacterial vaccines for mucosal immunization, p. 499-511. In H. Kiyono and M. F. Kagnoff (ed.), Essentials of mucosal immunology. Academic Press, San Diego, CA.
6 - Curtiss, R., III., S. B. Porter, M. Munson, S. A. Tinge, J. O. Hassan, C. Gentry-Weeks, and S. M. Kelly. 1991. Nonrecombinant and recombinant avirulent Salmonella live vaccines for poultry, p. 169-198. In L. C. Blankenship, J. S. Bailey, N. A. Cox, S. E. Craven, R. J. Meinersmann, and N. J. Stern (ed.), Colonization control of human bacterial enteropathogens in poultry. Academic Press, Inc., New York, NY.
7 - Denis, F., S. Badiane, J. P. Chiron, A. Sow, and I. D. Mar. 1977. Salmonella meningitis in infants. Lancet 1:910.[Medline]
8 - Fang, F. C., S. J. Libby, N. A. Buchmeier, P. C. Loewen, J. Switala, J. Harwood, and D. G. Guiney. 1992. The alternative sigma factor katF (rpoS) regulates Salmonella virulence. Proc. Natl. Acad. Sci. USA 89:11978-11982.[Abstract/Free Full Text]
9 - Galán, J. E., and R. Curtiss III. 1989. Cloning and molecular characterization of genes whose products allow Salmonella typhimurium to penetrate tissue culture cells. Proc. Natl. Acad. Sci. USA 86:6383-6387.[Abstract/Free Full Text]
10 - Galen, J. E., O. G. Gomez-Duarte, G. A. Losonsky, J. L. Halpern, C. S. Lauderbaugh, S. Kaintuck, M. K. Reymann, and M. M. Levine. 1997. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 15:700-708.[CrossRef][Medline]
11 - Gulig, P. A., and R. Curtiss III. 1987. Plasmid-associated virulence of Salmonella typhimurium. Infect. Immun. 55:2891-2901.[Abstract/Free Full Text]
12 - Gunn, B., X. Zhang, S. Y. Wanda, and R. Curtiss III. 2007. Safety of recombinant attenuated Salmonella vaccines (RASV) in infant mice, abstr. E-063, p. 278. Abstr. 107th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.
13 - Henderson, L. L. 1948. Salmonella meningitis: report of three cases and review of one hundred and forty-four cases from the literature. Am. J. Dis. Child. 75:351-375.[Abstract/Free Full Text]
14 - Hengge-Aronis, R. 2000. A role for the sigma S subunit of RNA polymerase in the regulation of bacterial virulence. Adv. Exp. Med. Biol. 485:85-93.[Medline]
15 - Hopkins, S., J. P. Kraehenbuhl, F. Schödel, A. Potts, D. Peterson, P. de Grandi, and D. Nardelli-Haefliger. 1995. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. 63:3279-3286.[Abstract]
16 - Kang, H. Y., C. M. Dozois, S. A. Tinge, T. H. Lee, and R. Curtiss III. 2002. Transduction-mediated transfer of unmarked deletion and point mutations through use of counterselectable suicide vectors. J. Bacteriol. 184:307-312.[Abstract/Free Full Text]
17 - Karim, M., and N. Islam. 2002. Salmonella meningitis: report of three cases in adults and literature review. Infection 30:104-108.[CrossRef][Medline]
18 - Kauffman, C. A., and R. J. St Hilaire. 1979. Salmonella meningitis. Occurrence in an adult. Arch. Neurol. 36:578-580.[Abstract/Free Full Text]
19 - Medina, E., and C. A. Guzman. 2001. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 19:1573-1580.[CrossRef][Medline]
20 - Mielcarek, N., S. Alonso, and C. Locht. 2001. Nasal vaccination using live bacterial vectors. Adv. Drug Delivery Rev. 51:55-69.[CrossRef][Medline]
21 - Olsen, S. J., R. Bishop, F. W. Brenner, T. H. Roels, N. Bean, R. V. Tauxe, and L. Slutsker. 2001. The changing epidemiology of Salmonella: trends in serotypes isolated from humans in the United States, 1987-1997. J. Infect. Dis. 183:753-761.[CrossRef][Medline]
22 - Pasetti, M. F., T. E. Pickett, M. M. Levine, and M. B. Sztein. 2000. A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model. Vaccine 18:3208-3213.[CrossRef][Medline]
23 - Pasetti, M. F., R. Salerno-Goncalves, and M. B. Sztein. 2002. Salmonella enterica serovar Typhi live vector vaccines delivered intranasally elicit regional and systemic specific CD8+ major histocompatibility class I-restricted cytotoxic T lymphocytes. Infect. Immun. 70:4009-4018.[Abstract/Free Full Text]
24 - Santander, J., S. Y. Wanda, C. A. Nickerson, and R. Curtiss III. 2007. Role of RpoS in fine-tuning the synthesis of Vi capsular polysaccharide in Salmonella enterica serotype Typhi. Infect. Immun. 75:1382-1392.[Abstract/Free Full Text]
25 - Sebastiani, G., V. Blais, V. Sancho, S. N. Vogel, M. M. Stevenson, P. Gros, J. M. Lapointe, S. Rivest, and D. Malo. 2002. Host immune response to Salmonella enterica serovar Typhimurium infection in mice derived from wild strains. Infect. Immun. 70:1997-2009.[Abstract/Free Full Text]
26 - Srinivasan, J., A. Nayak, R. Curtiss III, and S. Rubino. 1995. Effect of the route of immunization using recombinant Salmonella on mucosal and humoral immune responses, p. 273-280. In R. M. Chanock, F. Brown, H. S. Ginsberg, and E. Norrby (ed.), Vaccines 95. Cold Spring Harbor Laboratory Press, Plainview, NY.
27 - Tacket, C. O., D. M. Hone, R. Curtiss III, S. M. Kelly, G. Losonsky, L. Guers, A. M. Harris, R. Edelman, and M. M. Levine. 1992. Comparison of the safety and immunogenicity of
aroC
aroD and
cya
crp Salmonella typhi strains in adult volunteers. Infect. Immun. 60:536-541.[Abstract/Free Full Text] 28 - Uysal, H., A. Karademir, M. Kilinc, and O. Erturk. 2001. Salmonella encephalopathy with seizure and frontal intermittent rhythmic delta activity. Infection 29:103-106.[CrossRef][Medline]
29 - Vazquez-Torres, A., J. Jones-Carson, A. J. Bäumler, S. Falkow, R. Valdivia, W. Brown, M. Le, R. Berggren, W. T. Parks, and F. C. Fang. 1999. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. Nature 401:804-808.[CrossRef][Medline]
30 - Wickham, M. E., N. F. Brown, J. Provias, B. B. Finlay, and B. K. Coombes. 2007. Oral infection of mice with Salmonella enterica serovar Typhimurium causes meningitis and infection of the brain. BMC Infect. Dis. 7:65.[CrossRef][Medline]
Infection and Immunity, July 2008, p. 3268-3272, Vol. 76, No. 7
0019-9567/08/$08.00+0 doi:10.1128/IAI.00244-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.